Signoriello, E <br/><br/>
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.  [electronic resource] 

 -  Multiple sclerosis (Houndmills, Basingstoke, England)  06 2016 
 - 921-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1477-0970 
<br/><br/><label>Standard No.: </label>10.1177/1352458515604381  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Female<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Leukocyte Count<br/>Lymphocytosis--blood<br/>Magnetic Resonance Imaging<br/>Male<br/>Multiple Sclerosis, Chronic Progressive--blood<br/>Multiple Sclerosis, Relapsing-Remitting--blood<br/>Natalizumab--adverse effects<br/>Predictive Value of Tests<br/>Retrospective Studies<br/>Risk Factors<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult